Abstract
The MHC class I molecule, HLA-B27 can be expressed as a number of non-conventional forms, in addition to conventional HLA-B27 heterodimers presenting peptide. This has lead to new avenues of research to explain the association of this molecule with SpA. Surprisingly, HLA-B27 transgenic animal models implicated CD4+ T cells, which conventionally interact with MHC class II molecules, not MHC class I molecules, in the pathogenesis of SpA. One hypothesis to explain these finding is that non-conventional forms of HLA-B27, specifically HLA-B27 homodimers, might mimic MHC class II molecules and be recognised by CD4+ T cells. We investigated whether CD4+ T cells from AS patients can interact with HLA-B27, discovering that indeed CD4+ T cells can interact with various forms of HLA-B27. Here we discuss how such interactions between HLA-B27 and CD4+ T cells could occur in vivo and potential contributions of such interactions to the pathogenesis of SpA.
Keywords: HLA-B27, hypothesis, homodimers, T cells
Current Molecular Medicine
Title: The Recognition of Abnormal Forms of HLA-B27 by CD4+ T Cells
Volume: 4 Issue: 1
Author(s): Louise H. Boyle, Jane C. Goodall and J. S. Hill Gaston
Affiliation:
Keywords: HLA-B27, hypothesis, homodimers, T cells
Abstract: The MHC class I molecule, HLA-B27 can be expressed as a number of non-conventional forms, in addition to conventional HLA-B27 heterodimers presenting peptide. This has lead to new avenues of research to explain the association of this molecule with SpA. Surprisingly, HLA-B27 transgenic animal models implicated CD4+ T cells, which conventionally interact with MHC class II molecules, not MHC class I molecules, in the pathogenesis of SpA. One hypothesis to explain these finding is that non-conventional forms of HLA-B27, specifically HLA-B27 homodimers, might mimic MHC class II molecules and be recognised by CD4+ T cells. We investigated whether CD4+ T cells from AS patients can interact with HLA-B27, discovering that indeed CD4+ T cells can interact with various forms of HLA-B27. Here we discuss how such interactions between HLA-B27 and CD4+ T cells could occur in vivo and potential contributions of such interactions to the pathogenesis of SpA.
Export Options
About this article
Cite this article as:
Boyle H. Louise, Goodall C. Jane and Gaston S. Hill J., The Recognition of Abnormal Forms of HLA-B27 by CD4+ T Cells, Current Molecular Medicine 2004; 4 (1) . https://dx.doi.org/10.2174/1566524043479257
DOI https://dx.doi.org/10.2174/1566524043479257 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
CNS & Neurological Disorders - Drug Targets Epigenetic Regulations in the Pathogenesis of Periodontitis
Current Stem Cell Research & Therapy Role of Exosomes in Breast Cancer Management: Evidence-Based Review
Current Cancer Drug Targets Beneficial Effects of Herbs, Spices and Medicinal Plants on the Metabolic Syndrome, Brain and Cognitive Function
Central Nervous System Agents in Medicinal Chemistry Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Microglia and its Genetics in Alzheimer's Disease
Current Alzheimer Research Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Current Topics in Medicinal Chemistry Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model
Current Drug Targets Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation
Current Medicinal Chemistry Glucocorticoid Receptors and Bone
Current Pharmaceutical Design Indoleamine 2,3-Dioxygenase in Hematopoietic Stem Cell Transplantation
Current Drug Metabolism Celecoxib Upregulates Multidrug Resistance Proteins in Colon Cancer: Lack of Synergy with Standard Chemotherapy
Current Cancer Drug Targets The Evaluation of Animal Models in the Development of Anticancer Agents: From Preclinical to Clinical Tests
Current Cancer Drug Targets The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer’s Disease
Current Drug Discovery Technologies Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Isoform Selective Phosphoinositide 3-Kinase γ and δ Inhibitors and Their Therapeutic Potential
Recent Patents on Inflammation & Allergy Drug Discovery Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Preparation and Characterization of Binary and Ternary Complexes of Dihydroartremisinin with Hydroxypropyl-β-cyclodextrin, Palmitic acid and Polyvinylpyrrolidone K30
Current Pharmaceutical Analysis Up-Regulation of TLR-4 in the Brain After Ischemic Kidney-Induced Encephalopathy in the Rat
CNS & Neurological Disorders - Drug Targets